A comprehensive new review of global data has reaffirmed a long-standing medical consensus: screening for prostate cancer with the prostate-specific antigen (PSA) blood test can save lives, but the benefit is modest and comes with significant risks. The study highlights a delicate balance between preventing death and subjecting men to unnecessary treatments that can severely impact their quality of life.
The Numbers Behind the Benefit
The analysis, conducted by the Cochrane Library, examined six major trials involving nearly 800,000 men. The findings reveal that for every 1,000 men screened, two fewer men died from prostate cancer. In practical terms, this means 500 men must be screened to prevent a single death from the disease.
The benefit of screening is not immediate. It becomes statistically significant only after long-term monitoring, particularly evident in the European Randomized Study of Screening for Prostate Cancer (ERSPC), which tracked participants for 23 years.
“Prostate cancer screening does reduce prostate cancer mortality, although the caveat is that it takes a very extended period of time to realise that benefit,” said Prof Philipp Dahm, a urologist at the University of Minnesota and senior author of the review.
The Hidden Cost: Overdiagnosis and Harm
While the reduction in mortality is real, the “absolute benefit” is small compared to the potential for harm. The PSA test is imperfect; it cannot reliably distinguish between aggressive, life-threatening tumors and benign, slow-growing cancers that may never cause symptoms or shorten a man’s life.
This limitation leads to overdiagnosis —identifying cancers that do not need treatment. Consequently, many men undergo invasive procedures such as surgery, radiotherapy, or hormone therapy. These treatments carry serious risks, including:
- Urinary incontinence (loss of bladder control)
- Erectile dysfunction (impotence)
Data from the ProtecT trial indicates that between 8% and 47% of men experienced problems with urinary or sexual function following treatment. The Cochrane review noted that while their primary focus was mortality, the quality-of-life implications are substantial.
Dr. Juan Franco, the study’s first author, emphasized that these results are not a blanket endorsement for universal screening. Instead, they underscore the need for “shared decision-making,” where patients and doctors discuss the very real risks of overdiagnosis and unnecessary treatment.
Who Should Be Screened?
Prostate cancer is one of the most common cancers in men, with more than 64,000 cases diagnosed annually in the UK alone. One in eight men will develop the disease in their lifetime, rising to one in four for Black men.
Given the risks, most countries, including the UK, do not have formal national screening programs. The UK National Screening Committee recently advised against routine screening for most men, recommending it only for those with specific genetic mutations (BRCA1 and BRCA2) linked to aggressive cancers. Government ministers are currently reviewing this advice.
Experts suggest that screening makes the most sense for men who:
* Are expected to live at least another 10 to 15 years.
* Do not have other major health conditions that limit life expectancy.
“If you have a lot of competing medical comorbidities… you just don’t have to worry about prostate cancer for the most part, because most prostate cancer is slow growing,” explained Prof. Dahm.
The Future of Screening
The medical landscape is evolving. Newer methods aim to improve precision and reduce harm:
* Advanced Biomarkers: Tests looking for more prostate-specific proteins in the blood.
* MRI Imaging: Using magnetic resonance imaging to identify suspicious areas before biopsies.
* Active Surveillance: Monitoring slow-growing cancers closely rather than treating them immediately.
While these technologies look promising, researchers caution that it is too early to determine if they definitively save more lives or cause less harm than traditional PSA testing.
Conclusion
The debate over prostate cancer screening is not about whether it works, but whether the benefits outweigh the harms for the individual. The evidence shows that while PSA testing can prevent some deaths, it also leads to a significant number of unnecessary diagnoses and treatments with lasting side effects.
“This research shows again that this is not a simple decision, and we must be honest with men about the benefits but also about the potential harms,” said Dr. Matthew Hobbs at Prostate Cancer UK.
Ultimately, the goal is to empower men at risk to make informed, personalized choices about their health, ensuring that any screening decision aligns with their personal values and risk profile.
